Advances in MicroRNAs as Regulators, Biomarkers and Therapeutic Targets in Cardiovascular Diseases
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cells of the Cardiovascular System".
Deadline for manuscript submissions: closed (10 January 2024) | Viewed by 1418
Special Issue Editor
Interests: hypertension; coronary artery disease; atherosclerosis; metabolic syndrome; microRNAs; circulating microRNAs; gene expression; oxidative stress; ischemia-reperfusion
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cardiovascular diseases (CVD) are the leading cause of morbidity and mortality in the world. Although considerable progress has been made in the diagnosis, treatment, and prognosis of CVD, there is still a critical need for novel diagnostic biomarkers and new therapeutic interventions to decrease the incidence of this disease. microRNAs (miRNAs) are ~20–22 nucleotide RNA molecules with post-transcriptionally regulatory roles in physiological and pathological processes. In the last decade, miRNAs have emerged as novel and specific regulators of the cardiovascular system through interactions with important target genes of angiogenesis, cardiac cell contractility, and cell growth. Moreover, miRNA dysregulation has been described for several CVD, such as ischemia, stroke, hypertrophy, and cardiomyopathies. microRNAs have emerged as promising diagnostic and prognostic biomarkers for the noninvasive detection of CVD with high specificity and sensitivity and also as new therapeutic targets in CVD for translational studies and for clinical trials. This Special Issue aims to highlight miRNA as a novel tool with potential translation to the clinic which is related to the development and progression of cardiovascular disease.
Dr. Giulio Ceolotto
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- miRNA
- exosomes
- cardiovascular
- therapeutics
- gene expression
- biomarkers
- preclinical studies
- clinical trials
